10/17/2022 7:33:05 AM
Gilead Sciences, MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies
2/28/2022 7:13:41 AM
MacroGenics Promotes Eric Risser To COO
2/11/2021 4:42:22 PM
MacroGenics Adds Federica O’Brien To Its Board
7/18/2019 9:07:27 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $27 Price Target
6/5/2019 8:51:53 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $27 Up From $26 Price Target
5/16/2019 6:44:44 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $26 Price Target
5/3/2019 8:39:47 AM
Wedbush Ups MacroGenics Inc. (MGNX) To Outperform From Neutral With $26 Price Target
2/7/2019 8:24:09 AM
Wedbush Cuts MacroGenics Inc. (MGNX) To Neutral From Outperform With $26 Up From $20 Price Target
1/22/2019 7:49:39 AM
Wedbush Is Increasing MacroGenics Inc. (MGNX) FY18 Rev. Estimate To 60.3 M From 44.0 M
1/22/2019 7:49:15 AM
Wedbush Is Raising MacroGenics Inc. (MGNX) FY18 Estimate To -4.13 From -5.00
1/22/2019 7:30:49 AM
Wedbush Is Increasing MacroGenics Inc. (MGNX) Q4 18 Estimate To -0.95 From -1.21
1/22/2019 7:30:19 AM
Wedbush Reiterates MacroGenics Inc. (MGNX) At Outperform With $20 Down From $44 Price Target
5/8/2018 8:54:01 AM
Wedbush Is Lowering MacroGenics Inc. (MGNX) FY18 Rev. Estimate To 12.3 M From 15.7 M
5/8/2018 8:53:41 AM
Wedbush Is Lowering MacroGenics Inc. (MGNX) FY18 Estimate To -5.31 From -4.80
5/8/2018 8:53:25 AM
Wedbush Is Lowering MacroGenics Inc. (MGNX) Q4 18 Estimate To -1.39 From -1.17
5/8/2018 8:53:13 AM
Wedbush Is Lowering MacroGenics Inc. (MGNX) Q3 18 Estimate To -1.35 From -1.33